AstraZeneca, Cancer Research UK Fund $8.9M Cancer Rx Project with CRT, ICR

AstraZeneca and Cancer Research UK will contribute a combined £5.6 million ($8.9 million) to the Institute of Cancer Research to discover and develop cancer drugs that target molecular chaperones. AstraZeneca will have an exclusive worldwide license to compounds developed during the collaboration.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.